logo
logo

Yseop Announces Strategic Investment And Celebrates Milestone Of 150 Clinical Trials Powered By Generative Ai

Dec 07, 2023•over 1 year ago
New YorkInformation Technology

Description

Yseop, a world-leading Generative AI company for life sciences, today announces the closing of a strategic investment round, with new investor Novartis (dRx Capital), joining existing investors Eli Lilly, NextStage AM and Wille Finance and celebrates its involvement in more than 150 clinical trials across the leading pharmaceutical companies in the world. Included in these clinical trials are many of the most notable advancements in new treatments, vaccines, and medicines that society has seen in recent history.

Company Information

Company

Yseop

Location

New York, United States

About

Yseop is the leader in Generative AI for regulated industries, changing the way content automation solutions are delivered with a human-centric, AI platform. Yseop is reimagining the future of scientific writing to get medicine into the hands of those who need it faster. With a suite of industry-specific applications and cutting-edge hybrid Natural Language Generation (NLG) technology that blends symbolic, machine learning, and LLM techniques, Yseop ensures that even the most demanding content automation tasks are met with ease, scalability and application security across the entire enterprise. As the world’s leading content automation solution for biopharmaceuticals, Yseop Copilot is a digital colleague that empowers scientific writers and addresses the unique requirements of regulated industries. Blending the power of large language models with customer data, Yseop Copilot delivers trusted and auditable content automation solutions in a closed, secure environment.

Related People